CKLF like MARVEL transmembrane domain containing 3Genealiases: BNAS2 · CKLFSF3
Q-omics provides the consensus-scored CMTM3 profile across patient tissues and cancer cell-line models. CMTM3 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, CMTM3 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CMTM3 RNA expression shows 17,720 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, HNSC, and TGCT as cancer lineages where CMTM3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CMTM3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CMTM3 survival associations across molecular data types. CMTM3 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CMTM3 RNA expression–survival associations across cancer types. High CMTM3 expression shows unfavorable associations in MESO, ACC, LGG, STAD, LUSC and KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for CMTM3 RNA expression.
This table summarizes CMTM3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CMTM3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CMTM3 shows lower tumor expression in KICH and higher tumor expression in HNSC, THCA, KIRC, KIRP and STAD. The HNSC box plot shows higher CMTM3 RNA expression in tumor versus normal tissue (log2 FC = +1.526, t-test p < 0.001).
This table shows molecular features associated with CMTM3 in patient tissues and cancer cell lines. In patient samples, CMTM3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CMTM3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LUNG_NSCLC_LUAD.
